M28 Capital Management’s Stoke Therapeutics STOK Stock Holding History

M28 Capital Management’s Portfolio STOK Stock Details STOK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-346,190	Closed	-$3.68M	–	12
2023 Q2	$3.68M	Sell	346,190 -186,700	-35%	-$1.99M	4.86%	6
2023 Q1	$4.44M	Buy	532,890 +50,000	+10%	+$451K	5.02%	8
2022 Q4	$4.46M	Sell	482,890 -39,660	-8%	-$412K	4.25%	7
2022 Q3	$6.71M	Sell	522,550 -4,600	-0.9%	-$73.3K	7%	4
2022 Q2	$6.96M	Hold	527,150	–	–	7.81%	4
2022 Q1	$11.1M	Hold	527,150	–	–	10.2%	4
2021 Q4	$12.6M	Buy	+527,150	New	+$12.6M	9.87%	2

Other funds holding STOK

Skorpios Trust Limassol, Cyprus $53.2M AUM 90.96% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

M28 Capital Management's STOK Position: Q3 2023 in Review

M28 Capital Management sold out of Stoke Therapeutics (STOK) in Q3 2023, closing a stake of 346,190 shares — an estimated $3.68M sold.

M28 Capital Management first reported a position in STOK in Q4 2021 and held it in 7 quarters. The position peaked at $12.6M in Q4 2021. 96 funds tracked by Wall St. Rank hold STOK as of Q3 2023.

M28 Capital Management reported no remaining Stoke Therapeutics position as of Q3 2023 after selling out during the quarter.
M28 Capital Management sold 346,190 Stoke Therapeutics shares in Q3 2023, an estimated $3.68M.
M28 Capital Management first reported a position in Stoke Therapeutics in Q4 2021 and held it in 7 quarters.
M28 Capital Management's Stoke Therapeutics position peaked at $12.6M in Q4 2021.
96 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q3 2023.

Based on M28 Capital Management's 13F filing for Q3 2023, filed 13 Nov 2023.